



CHANGING THE WORLD, ONE PATIENT AT A TIME™



- A clinical stage pharmaceutical company developing an Anti-Cancer treatment with light activated PhotoDynamic Compounds ("PDC") and their associated drug formulation.
- Fully launched Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study.
- Focused on becoming the next standard of care for treating NMIBC.

Anti-Cancer Technology ("ACT") Development



**2015
2019**

TSX Venture 50
Company in
Clean Technology
& Life Sciences

540

Days cancer-free
status achieved by
2 patients in Phase
Ib NMIBC study

67%

Complete
Response rate in
Phase Ib NMIBC
study

10

Patients treated
in Phase II
NMIBC study, to
date

3

Canadian oncology
sites enrolled for
Phase II NMIBC, to
date

3+

Cancer indications
evaluated in pre-
clinical studies

12

Owned and
Licensed Patents

34

Patents Pending,
strengthening
Intellectual Property

14+

Published
Peer-Reviewed
Pre-clinical Studies

\$1.1B
USD
Estimated target
market³


**\$50K -
\$150K**
USD
Willingness to pay for
treatment⁴

\$17M
CAD
Latest capital
raised




Capital Structure on the Venture⁵ TSXV:TLT; OTCQB:TLTFF

Common Share Price: **C\$ 0.285**
Market Capital: **C\$ 58 M**
Shares Outstanding: **204,275,375**
Warrants: **91,814,705**
Options: **16,920,000**
Shares Fully Diluted: **313,010,080**
Insider Ownership: **7%** (9.3% fully diluted)
52 Week Range: **C\$ 0.21 - 0.61**



Drug + Laser Light Device = Anti-Cancer Treatment for NMIBC
(TLD-1433) (TLC-3200) 67% Complete Response rate at 540 days (Phase Ib)



⁽¹⁾ McFarland – Theralase Licence Agreement, Dated: September 11, 2011
⁽²⁾ U.S. Patent Nos. 9,345,769 and 9,676,806 and Canadian Patent No. 2,883,068 patents for "Metal-Based Thiophene Photodynamic Compounds and Their Use"
⁽³⁾ 2025 estimated bladder cancer market (US, France, Germany, Italy, Spain, UK & Japan). Source: Global Data: Bladder cancer market size to more than triple to over \$1.1 billion by 2025, April 2017.
⁽⁴⁾ Willingness to pay per quality adjusted life year (QALY) for competitor drug, Pembrolizumab. Source: Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer, July 2018
⁽⁵⁾ Stock information is provided by <https://web.tmxmoney.com>, as of February 25 2020